Andrew Schmidt
A5088471004- COVID-19 and healthcare impacts
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Healthcare cost, quality, practices
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Lung Cancer Treatments and Mutations
- Cancer survivorship and care
- SARS-CoV-2 and COVID-19 Research
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Childhood Cancer Survivors' Quality of Life
- Ovarian cancer diagnosis and treatment
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Palliative Care and End-of-Life Issues
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- Vascular Malformations Diagnosis and Treatment
Dana-Farber Cancer Institute
2020-2023
University of Rochester Medical Center
2023
Cairns Hospital
2020-2022
Harvard University
2020-2022
University of Kansas
2021-2022
Dana-Farber Brigham Cancer Center
2021-2022
Brigham and Women's Hospital
2021-2022
Wichita State University
2021
Roche (Switzerland)
2020
Bristol-Myers Squibb (Germany)
2020
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort patients and 2019 (COVID-19) reported to the COVID-19 Cancer Consortium (CCC19) identify prognostic clinical factors, including laboratory measurements anticancer therapies. active or historical laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March 18 November 2020 were included. The primary outcome was severity measured...
<h3>Importance</h3> COVID-19 is a life-threatening illness for many patients. Prior studies have established hematologic cancers as risk factor associated with particularly poor outcomes from COVID-19. To our knowledge, no beneficial role anti–COVID-19 interventions in this at-risk population. Convalescent plasma therapy may benefit immunocompromised individuals COVID-19, including those cancers. <h3>Objective</h3> evaluate the association of convalescent treatment 30-day mortality...
Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments 30-day all-cause mortality factors associated treatment. Logistic regression multiple adjustments (e.g., comorbidities, status, baseline severity) was performed. Hydroxychloroquine any other drug increased versus treatment than hydroxychloroquine or untreated controls; this not present alone. Remdesivir had numerically reduced controls that...
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary underlying malignancy or recent receipt of antineoplastic systemic therapies can result in less robust antibody titers following vaccination possible risk breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history cancer those on active immunosuppression (including chemotherapy), limited evidence available...
Background In this multicenter, single‐arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder upper tract carcinoma variant histology (BUTCVH), adrenal tumors, platinum‐refractory germ cell penile carcinoma, prostate cancer (NCT03333616). Methods Patients malignancies no prior immune checkpoint inhibitor exposure were enrolled. received at 3 mg/kg 1 intravenously every weeks for 4 doses,...
<h3>Importance</h3> Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize unique clinical course and outcomes in patients with cancer. <h3>Objective</h3> To investigate racial disparities severity presentation, complications, between non-Hispanic White cancer COVID-19. <h3>Design, Setting, Participants</h3> This retrospective cohort study used data from Cancer Consortium registry March 17, 2020,...
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized...
Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to worse outcomes associated during the pandemic. We sought evaluate clinical characteristics and patients who developed breakthrough after 2 or 3 doses mRNA vaccines.
To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) how their clinical decision making was influenced pandemic.An online survey conducted between March 24 April 29, 2020.A total of 343 28 countries participated. The median age 43 years (range, 29-68 years), majority were male (62%). At time survey, nearly all participants self-reported an outbreak in country (99.7%). Personal protective equipment available...
<h3>Importance</h3> Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing a potential tissue-based expression coreceptor transmembrane protease, serine 2 (TMPRSS2). <h3>Objective</h3> To examine whether ADT is associated decreased rate 30-day mortality from among cancer. <h3>Design, Setting, and Participants</h3> This cohort study analyzed patient data recorded COVID-19 Cancer Consortium registry between...
Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis treatment are well-known risk factors; however, a assessment model (RAM) for VTE in both is lacking. To assess the incidence factors thrombosis hospitalized COVID-19. Among Cancer Consortium registry (CCC19) cohort study, we assessed ATE within 90 days COVID-19-associated hospitalization. A multivariable logistic regression specifically was built using priori...
Systemic therapy for first-line metastatic renal cell carcinoma has evolved toward immune checkpoint blockade combinations incorporating a PD-1/L1 inhibitor along with CTLA-4 inhibition or VEGF-targeted therapy. The new treatment paradigm that integrates immunotherapy treatment-naïve advanced creates therapeutic challenge clinicians including the optimal way to integrate multidisciplinary care involving surgery, radiotherapy, and application of contemporaneous systemic in subsequent lines...
<h3>Importance</h3> The association between treatment with first-line immuno-oncology (IO) combination therapies and physician-assessed objective imaging response among patients metastatic renal cell carcinoma (mRCC) remains uncharacterized. <h3>Objective</h3> To compare the likelihood of (ie, complete or partial response) to IO ipilimumab-nivolumab (IOIO) therapy vs approved vascular endothelial growth factor inhibitor (IOVE) mRCC. <h3>Design, Setting, Participants</h3> This multicenter...
There are limited data evaluating the activity of cabozantinib (CABO) as second line (2L) therapy post standard care ipilimumab-nivolumab (IPI-NIVO) or immuno-oncology(IO)/vascular endothelial growth factor inhibitor (VEGFi) combinations (IOVE).Using IMDC database, we sought to identify objective response rate, time treatment failure (TTF) and overall survival (OS) 2L CABO after IPI-NIVO, IOVE combinations, pazopanib sunitinib (PAZ/SUN) other first (1L) therapies. Multivariable Cox...
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether COVID-19 increased by anticancer therapy, uncertain. Using data derived from the Cancer Consortium (CCC19), we show that patients treated for an compared control populations non-B-lymphoid malignancies. Among malignancies, those who received therapy within 12 months...
The frequency of coinfections and their association with outcomes have not been adequately studied among patients cancer coronavirus disease 2019 (COVID-19), a high-risk group for coinfection. We included adult (≥18 years) active or prior hematologic invasive solid malignancies laboratory-confirmed severe acute respiratory syndrome 2 (SARS-COV-2) infection, using data from the COVID-19 Cancer Consortium (CCC19, NCT04354701). captured within ±2 weeks diagnosis COVID-19, identified factors...
Abstract Aim Hospital admissions secondary to immune‐related adverse events (irAE) arising from immune checkpoint inhibitors (ICI) are likely increase with increasing use of this class drug. We sought determine the characteristics and outcomes hospital due irAE. Methods A retrospective analysis patients treated ICI at two tertiary hospitals in Queensland (Australia) was performed. Patients who received least one dose for a nonhaematological malignancy between 1st January 2016 2017 were...